Next, the individual contributions of GSK-3 isoforms to the regulation of NKG2DL in TKI-resistant CML cells was investigated using siRNAs specific for GSK-3α or GSK-3β to rule out potential off-target effect of GSK-3 inhibitor and probe the specific role of GSK-3. The gene discussed is GSK3A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.